FI3710058T3 - Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään - Google Patents

Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään Download PDF

Info

Publication number
FI3710058T3
FI3710058T3 FIEP18808075.8T FI18808075T FI3710058T3 FI 3710058 T3 FI3710058 T3 FI 3710058T3 FI 18808075 T FI18808075 T FI 18808075T FI 3710058 T3 FI3710058 T3 FI 3710058T3
Authority
FI
Finland
Prior art keywords
cbd
cannabidiol
treatment
lennox
lamotrigine
Prior art date
Application number
FIEP18808075.8T
Other languages
English (en)
Finnish (fi)
Inventor
Geoffrey Guy
Volker Knappertz
Original Assignee
Jazz Pharmaceuticals Res Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60788456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3710058(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Res Uk Limited filed Critical Jazz Pharmaceuticals Res Uk Limited
Application granted granted Critical
Publication of FI3710058T3 publication Critical patent/FI3710058T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FIEP18808075.8T 2017-11-15 2018-11-15 Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään FI3710058T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1718862.4A GB2568471B (en) 2017-11-15 2017-11-15 Use of cannabinoids in the treatment of epilepsy
PCT/GB2018/053315 WO2019097238A1 (en) 2017-11-15 2018-11-15 Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome

Publications (1)

Publication Number Publication Date
FI3710058T3 true FI3710058T3 (fi) 2024-11-11

Family

ID=60788456

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18808075.8T FI3710058T3 (fi) 2017-11-15 2018-11-15 Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään

Country Status (16)

Country Link
US (1) US20210169824A1 (enExample)
EP (2) EP3710058B1 (enExample)
JP (2) JP7391019B2 (enExample)
KR (1) KR102786614B1 (enExample)
CN (1) CN111629756A (enExample)
AU (2) AU2018366443A1 (enExample)
BR (1) BR112020009508A2 (enExample)
CA (1) CA3082433A1 (enExample)
DK (1) DK3710058T3 (enExample)
ES (1) ES2991947T3 (enExample)
FI (1) FI3710058T3 (enExample)
GB (1) GB2568471B (enExample)
IL (1) IL274633A (enExample)
MX (2) MX2020005147A (enExample)
RU (1) RU2020119390A (enExample)
WO (1) WO2019097238A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR102891881B1 (ko) 2020-07-16 2025-11-26 주식회사 엘지에너지솔루션 듀얼 슬롯 다이 코터
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
GB2597280A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
EP4412619A4 (en) * 2021-10-04 2025-11-12 Marinus Pharmaceuticals Inc GANAXOLONE FOR THE TREATMENT OF BOURNEVILLE'S TUBEROUS SCLEROSIS AND EPILEPTIC DISORDERS
EP4507689A1 (en) 2022-04-12 2025-02-19 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015266897B2 (en) 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
US20170224634A1 (en) * 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
JP2021502992A (ja) 2021-02-04
GB201718862D0 (en) 2017-12-27
WO2019097238A1 (en) 2019-05-23
GB2568471B (en) 2022-04-13
GB2568471A (en) 2019-05-22
EP4487860A3 (en) 2025-04-02
IL274633A (en) 2020-06-30
EP4487860A2 (en) 2025-01-08
MX2023012352A (es) 2023-10-31
DK3710058T3 (da) 2024-11-04
CA3082433A1 (en) 2020-05-15
AU2018366443A1 (en) 2020-06-11
AU2024216397A1 (en) 2024-09-19
BR112020009508A2 (pt) 2020-10-13
JP2023168448A (ja) 2023-11-24
CN111629756A (zh) 2020-09-04
US20210169824A1 (en) 2021-06-10
RU2020119390A3 (enExample) 2021-12-15
RU2020119390A (ru) 2021-12-15
EP3710058B1 (en) 2024-10-09
JP7391019B2 (ja) 2023-12-04
ES2991947T3 (es) 2024-12-05
MX2020005147A (es) 2020-08-20
KR102786614B1 (ko) 2025-03-26
KR20200088356A (ko) 2020-07-22
JP7723711B2 (ja) 2025-08-14
EP3710058A1 (en) 2020-09-23
NZ764569A (en) 2024-11-29

Similar Documents

Publication Publication Date Title
FI3710058T3 (fi) Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään
FI3743053T3 (fi) Kannabinoidien käyttö epilepsian hoidossa
FI3883563T3 (fi) Kannabidiolityyppinen kannabinoidiyhdiste
FI3641819T3 (fi) Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon
RU2012103603A (ru) Применение одного или комбинации фитоканнабиноидов для лечения эпилепсии
HRP20201230T1 (hr) Uporaba kanabinoida u liječenju atoničkih napadaja kod lennox-gastaut sindroma
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
FI4061344T3 (fi) 6-hydroksikannabidioli käytettäväksi lääkkeenä
MX387442B (es) Composiciones y tratamientos para el trastorno del sueño
MX386086B (es) Composicion de cannabis
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
MX386620B (es) Composicion de cannabis
GT201200164A (es) "nuevos compuestos de espiropiperidina"
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
DOP2006000170A (es) Nuevos derivados de espirocromanona
MX2022004935A (es) (+)- trans tetrahidrocannabinol ((+)-trans-thc) para uso como medicamento.
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
GT200900062A (es) Nuevos compuestos de diosmetina, un proceso para su preparacion y las composiciones farmaceuticas que los contienen
PH12020552162A1 (en) Thiophene derivatives for the treatment of disorders caused by ige
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
WO2017220042A3 (zh) 氨力农的药物组合物及其在高血压治疗中的应用
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MY160300A (en) Acylbenzene derivative